Gastrointestinal diseases are quite common all over the globe, and various treatments are available to tackle these health issues. One such way is the proper administration of a variety of drugs, thereby constituting a distinct gastrointestinal drugs market from a global perspective.

This market is mainly being driven due to rapidly progressing interests in research activities happening in drug development-based activities all over the globe. Moreover, cases of such ailments are quite common in old-aged people, and a rising geriatric population is also increasing the demand of such drugs. In addition, changing lifestyles, unhealthy eating habits, and increasing levels of stress also are key factors driving growth in the global gastrointestinal drugs market. With innovative advancements occurring in the techniques implemented for curing such issues at a steady pace, the global gastrointestinal drugs market is anticipated to register splendid revenue in the years to come.

As per expert analysts, the global gastrointestinal drugs market is foretold to clock revenue valuation of US$61.6 bn by 2024, which is a decent increase from an initial valuation of US$45.5 bn clocked in 2015. This growth is prophesized to occur at a healthy CAGR of 4.90% during the forecast period from 2016 to 2024.

gastrointestinal drugs market

Acid Neutralizers Come Out as Winning Segment in the Market

The global gastrointestinal drugs market is segregated into various segments on the basis of various criteria such as drug class, route of administration, disorder type, distribution channel, and regional spread. Under drug class, acid neutralizers, anti-diarrheal and laxatives, antiemetic and anti-nauseants, anti-inflammatory drugs, biologics, and antispasmodic, are key segments. Acid neutralizers are further subdivided into antacids, h2 antagonists, and proton pump inhibitors, in the form of sub-segments. In terms of administration route, oral, parenteral and rectal make up for the gastrointestinal drugs market. Under disorder type, gastro-esophageal reflux disease, inflammatory bowel disease, and irritable bowel syndrome, are prime illness types that require the administration of drugs. Whereas, the drugs are sold through three key distribution channels: hospital pharmacies, retail pharmacies, and online pharmacies.

Among all the drug classes, a rising demand for prevention of gastroesophageal reflux disease (GERD) has led to an increasing use of acid neutralizers. In this way, the acid neutralizers segment holds a dominant position in the global gastrointestinal drugs market. Moreover, the cost efficiency of such neutralizers too has contributed towards the segment’s splendid growth and presence in the market. Even in future, compared to other segments present under the drug class criteria, acid neutralizers are expected to continue gaining extensive revenue for the global gastrointestinal drugs market.

Region-wise, the global gastrointestinal drugs market is spread across North America, Latin America, Asia Pacific, Europe, and the Middle East and Africa. Of these, North America occupies the primary slot in terms of revenue generation in the market. This is mainly due to the presence of favorable reimbursement policies in this region, which are highly beneficial for the welfare of those affected by gastrointestinal issues. Moreover, rapidly increasing instances of various chronic diseases, wherein gastrointestinal problems might exist as a key symptom, also is a prime factor responsible for the market’s progress in North America. To be specific, the region had registered a share of more than 41% in 2016, compared to other regions. With a surge in the number of old-aged people present in North America, the sales of gastrointestinal drugs are prophesized to rapidly increase in the near future.

In terms of the vendor landscape, Abbott Laboratories, Allergan Plc, AstraZeneca, Bayer AG, Boehringer Ingelheim GmbH, GlaxoSmithKline Plc., Janssen Biotech Inc., Sanofi, Takeda Pharmaceutical, and Valeant Pharmaceuticals Inc. are chief players operating in the global gastrointestinal drugs market.

Augmented Research and Development Activities to Boost Gastrointestinal Drugs Market

Gastrointestinal disorders are quite prevalent all over the world and there are a variety of medications and treatment methods available to address these health problems. One such method is proper drug administration, which has resulted in the development of a distinct gastrointestinal drugs industry on a global scale.  This factor is likely to favour development of the global gastrointestinal drugs market in the years to come.

This demand is primarily motivated by the increasingly growing interest in drug development-related research activities taking place all over the world. Furthermore, such diseases are very prevalent in the elderly, and the need for such medicines is growing as the geriatric population grows. In addition, evolving diets, unhealthy dietary patterns, and the stress levels are all contributing to the expansion of the global gastrointestinal drugs market. With constant developments in the procedures used to treat such problems, the global gastrointestinal drugs market is expected to grow significantly in the coming years.

High Prevalence of GI Problems in the Geriatric Population to Spur Market Growth

The rising prevalence of gastrointestinal diseases around the world is a major factor in the gastrointestinal drugs market's growth. On the other hand, heavy funding, especially in scientific research for the expansion and advancement of these medicines, as well as increasing awareness about the efficacy of the therapies as well as the healing process, are significantly contributing to the growth of the market. In addition, technical advancements in the treatment process are expected to propel this market forward significantly in the coming years. The demand for these drugs is expected to rise due to an increase in the number of patients struggling with GI disorders as a result of dietary changes.

North America is expected to become the world's most active geographic market for gastrointestinal medicines.  It is expected to gain a sizable chunk of the gastrointestinal drugs market in the coming years as a result of customer-friendly payment programmes for the treatment of chronic syndromes or diseases. Because of the increasing number of elderly people who are vulnerable to gastrointestinal diseases, North America is expected to maintain its dominance in the gastrointestinal drugs market.

Global Gastrointestinal Drugs Market: Overview 

Gastro esophageal reflux disease (GERD), inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are types of gastrointestinal disease. gastro esophageal reflux disease (GERD) is a chronic gastric illness that arises when acidic juices in the stomach come back up into the esophagus from stomach, this can leads to irritation of esophagus and causes symptoms like heartburn, gas, etc. Inflammatory bowel disease is a group of chronic inflammation of small and large intestine. Ulcerative Colitis and Crohn’s disease are the two major types of inflammatory bowel disease. Irritable bowel syndrome (IBS) is a chronic condition that affects the colon (large intestine). Diarrhea, constipation, abdominal pain, cramping are the common symptoms of irritable bowel disease. 

The market overview section of the report comprises qualitative analysis of the overall gastrointestinal drugs market considering the factors determining the market dynamics such as drivers, restraints and opportunities, along with Porter’s five force analysis and market attractiveness analysis. In addition, such as market opportunity analysis for the drug class, route of administration, drug class, distribution channel, and key industry developments has also been provided. Key industry developments include the major events occurred in past 4-5 years and are expected to occur during the forecast period which are likely to affect the market dynamics. 

Global Gastrointestinal Drugs Market: Segmentation 

The global gastrointestinal drugs market has been segmented on the basis of drug class, route of administration, drug class, distribution channel. On the basis of drug class the global gastrointestinal drugs market is segmented into acid neutralizers, antidiarrheal and laxatives, antiemetic and antinauseants, anti-inflammatory drugs, biologics and others including antispasmodic etc. The acid neutralizer segment is again segmented as antacids, H2 antagonists and Proton pump inhibitors. On the basis of route of administration, the global gastrointestinal drugs market has been segmented into three types such as, oral, parenteral and rectal. Based on disorder type, the global gastrointestinal drugs market is segmented into gastro esophageal reflux disease, inflammatory bowel disease and Irritable bowel syndrome. On the basis of distribution channel, the global gastrointestinal drugs market is segmented as hospital pharmacies, retail pharmacies and online pharmacies. 

The market for these drug class, route of administration, disorder type, and distribution channel has been extensively analyzed on the basis of factors such as usage pattern, sales revenue, and geographic presence and product developments. The market size and forecast in terms of revenue (US$ million), for each of these segments, and the sub-segments have been provided for the period 2014 to 2024, considering 2015 as the base year. The report also provides the compounded annual growth rate (CAGR) for each segment for the forecast period 2016 to 2024. 

Geographically, the gastrointestinal drugs market has been classified into five segments, namely, North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa. The market size forecast for each region has been provided for the period 2014 to 2024, in terms of drug class, route of administration, disorder type, and distribution channel, along with the CAGR (%) for the forecast period 2016 to 2024. 

Global Gastrointestinal Drugs Market: Competitive Analysis 

The report also provides a section on the competitive landscape, wherein the market share analysis of leading players in the global gastrointestinal drugs market, in terms of percentage share in 2016 (estimated) has been discussed. A list of recommendations has also been included for new entrants as well as existing market players to help them establish a strong presence in the market and increase their market share. 

The report concludes with the profiles of major players in the global gastrointestinal drugs market such as Takeda pharmaceutical, Valeant Pharmaceuticals International, Inc., Janssen Biotech, Inc., Bayer AG, Sanofi, AstraZeneca, Allergan Plc, GlaxoSmithKline, Abbott Laboratories, Boehringer Ingelheim GmbH and Allergan Plc., among others. The major market players are evaluated on various parameters such as company overview, financial overview, product portfolio, business strategies and recent developments.

This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.

Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:

  • Customer Experience Maps
  • Insights and Tools based on data-driven research
  • Actionable Results to meet all the business priorities
  • Strategic Frameworks to boost the growth journey

The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.

The following regional segments are covered comprehensively:

  • North America
  • Asia Pacific
  • Europe
  • Latin America
  • The Middle East and Africa

The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.

Below is a snapshot of these quadrants.

1. Customer Experience Map

The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.

2. Insights and Tools

The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.

3. Actionable Results

The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.

4. Strategic Frameworks

The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.

The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:

1. What can be the best investment choices for venturing into new product and service lines?

2. What value propositions should businesses aim at while making new research and development funding?

3. Which regulations will be most helpful for stakeholders to boost their supply chain network?

4. Which regions might see the demand maturing in certain segments in near future?

5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?

6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?

7. Which government regulations might challenge the status of key regional markets?

8. How will the emerging political and economic scenario affect opportunities in key growth areas?

9. What are some of the value-grab opportunities in various segments?

10. What will be the barrier to entry for new players in the market?

The global gastrointestinal drugs market is segmented as follows: 

By Drug Class

  • Acid Neutralizers
    • Antacids
    • H2 antagonists
    • Proton pump inhibitors
  • Antidiarrheal and Laxatives
  • Antiemetic and Antinauseants
  • Anti-inflammatory drugs
  • Biologics
  • Others (Antispasmodic etc.) 

By Route of Administration

  • Oral
  • Parenteral
  • Rectal 

By Disorder Type

  • Gastro Esophageal Reflux Disease
  • Inflammatory Bowel Disease
  • Irritable Bowel Syndrome 

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies 

By Region

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Russia
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia & New Zealand
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
    • Southern Global
  • Middle East & Africa
    • GCC countries
    • South Africa
    • Rest of Middle East & Africa

With a robust experience in creating exceptional market reports, Transparency Market Research has emerged as one of the trusted market research companies among a large number of stakeholders and CXOs. Every report at Transparency Market Research goes through rigorous research activity in every aspect. The researchers at TMR keep a close watch on the market and extract beneficial growth-boosting points. These points help the stakeholders to strategize their business plans accordingly.

TMR researchers conduct exhaustive qualitative and quantitative research. This research involves taking inputs from the experts in the market, focused attention on recent developments, and others. This method of research makes TMR stand out from other market research firms.

Here's how Transparency Market Research helps the stakeholders and CXOs through the reports:

Inculcation and Evaluation of Strategic Collaborations: The TMR researchers analyze recent strategic activities like mergers, acquisitions, partnerships, collaborations, and joint ventures. All the information is compiled and included in the report.

Perfect Market Size Estimations: The report analyzes the demographics, growth potential, and capability of the market through the forecast period. This factor leads to the estimation of the market size and also provides an outline about how the market will retrieve growth during the assessment period.

Investment Research: The report focuses on the ongoing and upcoming investment opportunities across a particular market. These developments make the stakeholders aware of the current investment scenario across the market.

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Gastrointestinal Drugs Market

4. Market Overview
     4.1. Introduction
            4.1.1. Product Definition
            4.1.2. Industry Evolution / Developments
     4.2. Gastrointestinal Drugs Market Overview

5. Market Dynamics
     5.1. Drivers
            5.1.1. Restraints
            5.1.2. Opportunity
            5.1.3. Trends 
     5.2. Porter’s Five Force Analysis
     5.3. FDA Approved Biologics Products
     5.4. Overview of Clinical Trials
     5.5. Epidemiology of Gastrointestinal Disease: Global Scenario
     5.6. Global prevalence of Inflammatory Bowel Disease in 2015

6. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Drug Class
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Key Trends
     6.4. Market Size (US$ Mn) Forecast By Drug Class
            6.4.1. Acid Neutralizers
                      6.4.1.1. Antacids
                      6.4.1.2. H2 antagonists
                      6.4.1.3. Proton pump inhibitors
                      6.4.1.4. Helicobacter pylori eradication
            6.4.2. Antidiarrheal and Laxatives
            6.4.3. Antiemetic and Antinauseants
            6.4.4. Anti-inflammatory drugs
            6.4.5. Biologics
            6.4.6. Others (Antispasmodic etc.)
     6.5. Market Attractiveness By Drug Class

7. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Route of Administration
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Key Trends
     7.4. Market Size (US$ Mn) Forecast By Route of Administration
            7.4.1. Oral
            7.4.2. Intravenous
            7.4.3. Rectal
     7.5. Market Attractiveness By Route of Administration

8. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Disorder Type
     8.1. Introduction & Definition     
     8.2. Key Findings / Developments
     8.3. Key Trends
     8.4. Market Size (US$ Mn) Forecast By Disorder Type
            8.4.1. Gastroesophageal Reflux Disease
            8.4.2. Inflammatory Bowel Disease
            8.4.3. Irritable Bowel Syndrome
     8.5. Market Attractiveness By Disorder Type

9. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Distribution Channel
     9.1. Introduction & Definition
     9.2. Key Findings / Developments
     9.3. Key Trends
     9.4. Market Size (US$ Mn) Forecast By Distribution Channel
            9.4.1. Hospital Pharmacies
            9.4.2. Retail Pharmacies
            9.4.3. Online Pharmacies
     9.5. Market Attractiveness By Distribution Channel

10. Global Gastrointestinal Drugs Market Analysis and Forecasts, By Region
     10.1. Key Findings
     10.2. Policies and Regulations
     10.3. Market Size (US$ Mn) Forecast By Region
            10.3.1. North America
            10.3.2. Latin America
            10.3.3. Europe
            10.3.4. Asia Pacific
            10.3.5. Middle East and Africa
     10.4. Market Attractiveness By Country/Region

11. North America Gastrointestinal Drugs Market Analysis and Forecast     
     11.1. Key Findings
     11.2. Policies and Regulations     
     11.3. Key Trends
     11.4. Market Value Forecast By Country
            11.4.1. US
            11.4.2. Canada
     11.5. Market Size (US$ Mn) Forecast By Drug Class
            11.5.1. Acid Neutralizers
                      11.5.1.1. Antacids
                      11.5.1.2. H2 antagonists
                      11.5.1.3. Proton pump inhibitors
                      11.5.1.4. Helicobacter pylori eradication
            11.5.2. Antidiarrheal and Laxatives
            11.5.3. Antiemetic and Antinauseants
            11.5.4. Anti-inflammatory drugs
            11.5.5. Biologics
            11.5.6. Others (Antispasmodic etc.)
     11.6. Market Size (US$ Mn) Forecast By Route of Administration
            11.6.1. Oral
            11.6.2. Intravenous
            11.6.3. Rectal
     11.7. Market Size (US$ Mn) Forecast By Disorder Type
            11.7.1. Gastroesophageal Reflux Disease
            11.7.2. Inflammatory Bowel Disease
            11.7.3. Irritable Bowel Syndrome
     11.8. Market Size (US$ Mn) Forecast By Distribution Channel
            11.8.1. Hospital Pharmacies
            11.8.2. Retail Pharmacies
            11.8.3. Online Pharmacies
     11.9. Market Attractiveness Analysis 
            11.9.1. By Country
            11.9.2. By Drug Class
            11.9.3. By Route of Administration
            11.9.4. By Disorder Type
            11.9.5. By Distribution Channel

12. Europe Gastrointestinal Drugs Market Analysis and Forecast
     12.1. Key Findings
     12.2. Policies and Regulations
     12.3. Key Trends
     12.4. Market Value Forecast By Country
            12.4.1. Germany
            12.4.2. France
            12.4.3. U.K.
            12.4.4. Italy
            12.4.5. Russia
            12.4.6. Spain
            12.4.7. Rest of Europe
     12.5. Market Size (US$ Mn) Forecast By Drug Class
            12.5.1. Acid Neutralizers
                      12.5.1.1. Antacids
                      12.5.1.2. H2 antagonists
                      12.5.1.3. Proton pump inhibitors
                      12.5.1.4. Helicobacter pylori eradication
            12.5.2. Antidiarrheal and Laxatives
            12.5.3. Antiemetic and Antinauseants
            12.5.4. Anti-inflammatory drugs
            12.5.5. Biologics
            12.5.6. Others (Antispasmodic etc.)
     12.6. Market Size (US$ Mn) Forecast By Route of Administration
            12.6.1. Oral
            12.6.2. Intravenous
            12.6.3. Rectal
     12.7. Market Size (US$ Mn) Forecast By Disorder Type
            12.7.1. Gastroesophageal Reflux Disease
            12.7.2. Inflammatory Bowel Disease
            12.7.3. Irritable Bowel Syndrome
     12.8. Market Size (US$ Mn) Forecast By Distribution Channel
            12.8.1. Hospital Pharmacies
            12.8.2. Retail Pharmacies
            12.8.3. Online Pharmacies
     12.9. Market Attractiveness Analysis 
            12.9.1. By Country
            12.9.2. By Drug Class
            12.9.3. By Route of Administration
            12.9.4. By Disorder Type
            12.9.5. By Distribution Channel

13. Asia Pacific Gastrointestinal Drugs Market Analysis and Forecast
     13.1. Key Findings
     13.2. Policies and Regulations
     13.3. Key Trends
     13.4. Market Value Forecast By Country
            13.4.1. China
            13.4.2. Japan
            13.4.3. India
            13.4.4. Australia & New Zealand
            13.4.5. India
            13.4.6. Rest of Asia Pacific
     13.5. Market Size (US$ Mn) Forecast By Drug Class
            13.5.1. Acid Neutralizers
                      13.5.1.1. Antacids
                      13.5.1.2. H2 antagonists
                      13.5.1.3. Proton pump inhibitors
                      13.5.1.4. Helicobacter pylori eradication
            13.5.2. Antidiarrheal and Laxatives
            13.5.3. Antiemetic and Antinauseants
            13.5.4. Anti-inflammatory drugs
            13.5.5. Biologics
            13.5.6. Others (Antispasmodic etc.)
     13.6. Market Size (US$ Mn) Forecast By Route of Administration
            13.6.1. Oral
            13.6.2. Intravenous
            13.6.3. Rectal
     13.7. Market Size (US$ Mn) Forecast By Disorder Type
            13.7.1. Gastroesophageal Reflux Disease
            13.7.2. Inflammatory Bowel Disease
            13.7.3. Irritable Bowel Syndrome
     13.8. Market Size (US$ Mn) Forecast By Distribution Channel
            13.8.1. Hospital Pharmacies
            13.8.2. Retail Pharmacies
            13.8.3. Online Pharmacies
     13.9. Market Attractiveness Analysis 
            13.9.1. By Country
            13.9.2. By Drug Class
            13.9.3. By Route of Administration
            13.9.4. By Disorder Type
            13.9.5. By Distribution Channel

14. Latin America Gastrointestinal Drugs Market Analysis and Forecast
     14.1. Key Findings
     14.2. Policies and Regulations
     14.3. Key Trends
     14.4. Market Value Forecast By Country
            14.4.1. Brazil
            14.4.2. Mexico
            14.4.3. Rest of Latin America
     14.5. Market Size (US$ Mn) Forecast By Drug Class
            14.5.1. Acid Neutralizers
                      14.5.1.1. Antacids
                      14.5.1.2. H2 antagonists
                      14.5.1.3. Proton pump inhibitors
                      14.5.1.4. Helicobacter pylori eradication
            14.5.2. Antidiarrheal and Laxatives
            14.5.3. Antiemetic and Antinauseants
            14.5.4. Anti-inflammatory drugs
            14.5.5. Biologics
            14.5.6. Others (Antispasmodic etc.)
     14.6. Market Size (US$ Mn) Forecast By Route of Administration
            14.6.1. Oral
            14.6.2. Intravenous
            14.6.3. Rectal
     14.7. Market Size (US$ Mn) Forecast By Disorder Type
            14.7.1. Gastroesophageal Reflux Disease
            14.7.2. Inflammatory Bowel Disease
            14.7.3. Irritable Bowel Syndrome
     14.8. Market Size (US$ Mn) Forecast By Distribution Channel
            14.8.1. Hospital Pharmacies
            14.8.2. Retail Pharmacies
            14.8.3. Online Pharmacies
     14.9. Market Attractiveness Analysis 
            14.9.1. By Country
            14.9.2. By Drug Class
            14.9.3. By Route of Administration
            14.9.4. By Disorder Type
            14.9.5. By Distribution Channel

15. Middle East & Africa Gastrointestinal Drugs Market Analysis and Forecast
     15.1. Key Findings
     15.2. Policies and Regulations
     15.3. Key Trends
     15.4. Market Value Forecast By Country
            15.4.1. GCC countries 
            15.4.2. South Africa
            15.4.3. Rest of Middle East & Africa
     15.5. Market Size (US$ Mn) Forecast By Drug Class
            15.5.1. Acid Neutralizers
                      15.5.1.1. Antacids
                      15.5.1.2. H2 antagonists
                      15.5.1.3. Proton pump inhibitors
                      15.5.1.4. Helicobacter pylori eradication
            15.5.2. Antidiarrheal and Laxatives
            15.5.3. Antiemetic and Antinauseants
            15.5.4. Anti-inflammatory drugs
            15.5.5. Biologics
            15.5.6. Others (Antispasmodic etc.)
     15.6. Market Size (US$ Mn) Forecast By Route of Administration
            15.6.1. Oral
            15.6.2. Intravenous
            15.6.3. Rectal
     15.7. Market Size (US$ Mn) Forecast By Disorder Type
            15.7.1. Gastroesophageal Reflux Disease
            15.7.2. Inflammatory Bowel Disease
            15.7.3. Irritable Bowel Syndrome
     15.8. Market Size (US$ Mn) Forecast By Distribution Channel
            15.8.1. Hospital Pharmacies
            15.8.2. Retail Pharmacies
            15.8.3. Online Pharmacies
     15.9. Market Attractiveness Analysis 
            15.9.1. By Country
            15.9.2. By Drug Class
            15.9.3. By Route of Administration
            15.9.4. By Disorder Type
            15.9.5. By Distribution Channel

16. Competition Landscape
     16.1. Market Player 
     16.2. Company Share Analysis (2016)
     16.3. Company Profiles 
            16.3.1. Abbott Laboratories 
                      16.3.1.1. Overview
                      16.3.1.2. Financials
                      16.3.1.3. Recent Developments
                      16.3.1.4. Strategy
            16.3.2. Allergan Plc 
                      16.3.2.1. Overview
                      16.3.2.2. Financials
                      16.3.2.3. Recent Developments
                      16.3.2.4. Strategy
            16.3.3. AstraZeneca 
                      16.3.3.1. Overview
                      16.3.3.2. Financials
                      16.3.3.3. Recent Developments
                      16.3.3.4. Strategy
            16.3.4. Bayer AG 
                      16.3.4.1. Overview
                      16.3.4.2. Financials
                      16.3.4.3. Recent Developments
                      16.3.4.4. Strategy
            16.3.5. Boehringer Ingelheim GmbH 
                      16.3.5.1. Overview
                      16.3.5.2. Financials
                      16.3.5.3. Recent Developments
                      16.3.5.4. Strategy
            16.3.6. GlaxoSmithKline plc 
                      16.3.6.1. Overview
                      16.3.6.2. Financials
                      16.3.6.3. Recent Developments
                      16.3.6.4. Strategy
            16.3.7. Janssen Biotech, Inc. 
                      16.3.7.1. Overview
                      16.3.7.2. Financials
                      16.3.7.3. Recent Developments
                      16.3.7.4. Strategy
            16.3.8. Sanofi
                      16.3.8.1. Overview
                      16.3.8.2. Financials
                      16.3.8.3. Recent Developments
                      16.3.8.4. Strategy
            16.3.9. Takeda Pharmaceutical 
                      16.3.9.1. Overview
                      16.3.9.2. Financials
                      16.3.9.3. Recent Developments
                      16.3.9.4. Strategy
            16.3.10. Valeant Pharmaceuticals, Inc.
                      16.3.10.1. Overview
                      16.3.10.2. Financials
                      16.3.10.3. Recent Developments
                      16.3.10.4. Strategy

List of Tables

Table 01: Biologics Products, Manufacturers & Trade Names 
Table 02: Biologics Products, Manufacturers & Trade Names 
Table 03: Overview of major clinical trials for Inflammatory Bowel Disease
Table 04: Overview of major clinical trials for Inflammatory Bowel Disease
Table 05: Overview of major clinical trials for Inflammatory Bowel Disease
Table 06: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 07: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizer (Drug Class), 2014–2024
Table 08: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 09: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 10: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 11: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Region, 2014–2024
Table 12: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 13: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 14: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014–2024
Table 15: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 16: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 17: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 18: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 19: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 20: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014–2024
Table 21: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 22: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 23: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 24: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 25: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 26: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class),
Table 27: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 28: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 29: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 30: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 31: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 32: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers (Drug Class), 2014-2024
Table 33: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 34: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 35: Latin America Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024
Table 36: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Country, 2014–2024
Table 37: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Drug Class, 2014–2024
Table 38: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Acid Neutralizers, 2014–2024
Table 39: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Route of Administration, 2014–2024
Table 40: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Disorder Type, 2014–2024
Table 41: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast, by Distribution Channel, 2014–2024

List of Figures

Figure 01: Market Value Share, by Drug Class (2015)
Figure 02: Market Value Share, by Route of Administration (2015)
Figure 03: Market Value Share, by Disorder Type (2015)
Figure 04: Market Value Share, by Distribution Channel (2015)
Figure 05: Market Value Share, by Region (2015)
Figure 06: Global Gastrointestinal Drugs Market Size (US$ Mn) Forecast, 2014–2024
Figure 07: Global Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 08: Global Acid Neutralizers Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 09: Global Antidiarrheal and Laxatives Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 10: Global Antiemetic and Antinauseants Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 11: Global Anti-inflammatory drugs Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 12: Global Biologics Market Revenue (US$ Mn) and
Figure 13: Global Others (Antispasmodic etc.)Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 14: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class
Figure 15: Global Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 16: Global Oral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 17: Global Parenteral Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 18: Global Rectal Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 19: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 20: Global Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 21: Global Gastroesophageal Reflux Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 22: Global Inflammatory Bowel Disease Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 23: Global Irritable Bowel Syndrome Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 24: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Disorder Type, 2016–2024
Figure 25: Global Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 26: Global Hospital Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 27: Global Retail Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 28: Global Online Pharmacies Market Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2024
Figure 29: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Distribution Channel, 2016–2024
Figure 30: Global Gastrointestinal Drugs Market Value Share Analysis, by Region, 2016 and 2024
Figure 31: Global Gastrointestinal Drugs Market Attractiveness Analysis, by Region
Figure 32: North America Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 33: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 34: North America Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 35: North America Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 36: North America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 37: North America Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 38: North America Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 39: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 40: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 41: North America Gastrointestinal Drugs Market Attractiveness Analysis, by Disorder Type, 2016–2024
Figure 42: North America Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 43: Europe Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 44: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2015
Figure 45: Europe Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 46: Europe Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 47: Europe Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 48: Europe Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 49: Europe Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 50: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 51: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 52: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 53: Europe Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 54: Asia Pacific Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 55: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 56: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 57: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 58: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 59: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 60: Asia Pacific Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 61: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 62: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 63: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 64: Asia Pacific Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 66: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 67: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 68: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 69: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 70: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 71: Latin America Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 72: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 73: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 74: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 75: Latin America Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 76: Middle East & Africa Gastrointestinal Drugs Market Size (US$ Mn) Forecast and Y-o-Y Growth (%), 2014–2024
Figure 77: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Country, 2016–2024
Figure 78: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Country, 2016 and 2024
Figure 79: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Drug Class, 2016 and 2024
Figure 80: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Route of Administration, 2016 and 2024
Figure 81: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Disorder Type, 2016 and 2024
Figure 82: Middle East & Africa Gastrointestinal Drugs Market Value Share Analysis, by Distribution Channel, 2016 and 2024
Figure 83: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Drug Class, 2016–2024
Figure 84: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by Route of Administration, 2016–2024
Figure 85: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by disorder type, 2016–2024
Figure 86: Middle East & Africa Gastrointestinal Drugs Market Attractiveness Analysis, by distribution channel, 2016–2024
Figure 87: Global Gastrointestinal Drugs Market Share Analysis, by Company, 2016 (Estimated)

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.

Request Customization

Gastrointestinal Drugs Market